Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Harmine is a beta-carboline alkaloid that inhibits DYRK1A enzyme activity, promoting pancreatic beta-cell proliferation and regeneration. This compound shows promise for diabetes management by enhancing insulin-producing cell mass and function.
Origin & History
Harmine is a beta-carboline alkaloid naturally found in Peganum harmala (Syrian rue) and plants used in traditional ayahuasca preparations. It can be extracted from these plant sources or synthesized as pharmaceutical-grade material for clinical research applications.
Research Narrative (Provisional)
Mount Sinai researchers conducted a Phase 1 open-label trial in 25 healthy adults testing pure pharmaceutical-grade harmine, finding no psychoactive effects but dose-dependent gastrointestinal side effects. In July 2024, researchers published findings in Science Translational Medicine demonstrating harmine combined with exenatide increased human beta-cell mass and function in diabetic mice models, with effects lasting at least one month post-treatment.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Harmine is a pure bioactive alkaloid compound (beta-carboline class), not a nutritional food ingredient, and therefore has no macronutrient, micronutrient, fiber, or caloric profile in the conventional dietary sense. As an isolated phytochemical, it is typically encountered in research or supplemental contexts at pharmacologically relevant doses. Key compositional facts: Molecular formula C13H12N2O, molecular weight 212.25 g/mol, naturally occurring as a crystalline solid. Found endogenously in plants such as Peganum harmala (Syrian rue) at concentrations of approximately 2–7% dry weight of seeds, and in Banisteriopsis caapi vine at approximately 0.31–8.43 mg/g dry weight. As a pure compound, it contains no vitamins, minerals, dietary fiber, or protein. Bioactive concentration in research contexts: in vitro studies use concentrations typically ranging from 1–10 μM; preclinical animal studies utilize doses in the range of 10–80 mg/kg body weight. Bioavailability notes: Harmine is lipophilic, readily crosses the blood-brain barrier, and is metabolized primarily via CYP1A2-mediated demethylation to harmol in the liver; oral bioavailability is moderate and subject to first-pass metabolism. It acts as a reversible inhibitor of monoamine oxidase A (MAO-A) and a potent DYRK1A kinase inhibitor at nanomolar concentrations (IC50 approximately 33–80 nM for DYRK1A).
Reported Mechanism (Provisional)
Harmine inhibits dual-specificity tyrosine-regulated kinase 1A (DYRK1A), a key enzyme that normally suppresses beta-cell proliferation in the pancreas. By blocking DYRK1A activity, harmine removes the molecular brake on cell division, allowing adult pancreatic beta-cells to proliferate and regenerate. This mechanism synergizes with GLP-1 receptor agonists to enhance overall beta-cell mass and insulin secretion capacity.
Clinical Narrative (Provisional)
Current evidence for harmine comes primarily from preclinical studies and cell culture experiments rather than human clinical trials. Laboratory studies demonstrate significant increases in beta-cell proliferation rates and improved glucose tolerance in animal models. Research shows that harmine combined with GLP-1 receptor agonists produces sustained effects lasting at least one month after treatment discontinuation. However, human safety and efficacy data remain limited, requiring further clinical investigation before therapeutic recommendations can be made.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.